Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in COVID-19 Patients with Pneumonia. A Randomized and Controlled Clinical Trial

  1. Leticia R. Cruz
  2. Idania Baladrón
  3. Aliusha Rittoles
  4. Pablo A. Díaz
  5. Carmen Valenzuela
  6. Raúl Santana
  7. Maria M. Vázquez
  8. Ariadna García
  9. Deyli Chacón
  10. Delvin Thompson
  11. Gustavo Perera
  12. Ariel González
  13. Rafael Reyes
  14. Loida Torres
  15. Jesus Pérez
  16. Yania Valido
  17. Ralysmay Rodriguez
  18. Dania M. Vázquez-Bloomquist
  19. Mauro Rosales
  20. Ailyn C. Ramón
  21. George V. Pérez
  22. Gerardo Guillén
  23. Verena Muzio
  24. Yasser Perera
  25. Silvio E. Perea
  26. ATENEA-Co-300 Group

Reviewed by

Read the full article See related articles

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1021/acsptsci.0c00175
  2. Version published to 10.1101/2020.09.03.20187112v2 on medRxiv
  3. ScreenIT

    SciScore for 10.1101/2020.09.03.20187112: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board StatementIRB: The Ethics Committee for Clinical Research in the hospital and Cuban Regulatory Agency (
    Consent: All patients met the inclusion criteria described in the protocol and signed the informed consent.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variablenot detected.

    Table 2: Resources

    Software and Algorithms
    SentencesResources
    The analysis was performed using SPSS 25.0 software and EPIDAT 3.1.
    SPSS
    suggested: (SPSS, RRID:SCR_002865)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a protocol registration statement.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  4. Version published to 10.1101/2020.09.03.20187112v1 on medRxiv